Business
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic
Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic
About this update from Absci Corporation
[{"type":"text","content":"Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic antibody treatment\nVANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, announced the launch of an endometriosis advisory board for its ABS-201 program in clinical development for endometriosis. The Advisory Board consists of endometriosis and clinical development experts with backgrounds from renowned institutions including the Yale University School of Medicine, Duke University School of Medicine, UCSF, and the Mayo Clinic. Endometriosis is a chronic, painful inflammatory disease defined by endometrium-like lesions found outside the uterus affecting an estimated 190 million worldwide. The current standard of care relies on hormonal therapies, GnRH agonists, and over-the-counter pain medications, none of which targets the underlying pathology driving the condition. The gap between patient need and available options underscores the urgency for a fundamentally different therapeutic approach. ABS-201 is an anti-prolactin receptor (anti-PRLR) antibody designed to target a distinct, non-hormonal pathway in endometriosis. Prolactin receptor signaling is locally upregulated in ectopic endometrial tissue, where it drives inflammation and lesion survival independent of the hormonal suppression axis targeted by current therapies. By blocking this pathway, ABS-201 has the potential to treat endometriosis without suppressing ovulation or fertility—a critical unmet need for the large population of patients of reproductive age. ABS-201 is formulated for subcutaneous self-administration with an extended half-life demonstrated in non-human primates, designed to support infrequent dosing and patient convenience outside of clinical settings. “Today, every approved endometriosis therapy works through hormonal suppression—forcing patients to choose between managing their disease and preserving fertility. ABS-201 targets a fundamentally different pathway, and this Advisory Board of world-class leaders in reproductive medicine will help us design studies that demonstrate that differentiation where it matters most: in patient outcomes,” said Sean M...